Inhibition of protease-activated receptor 1 ameliorates behavioral deficits and restores hippocampal synaptic plasticity in a rat model of status epilepticus

Neurosci Lett. 2019 Jan 23:692:64-68. doi: 10.1016/j.neulet.2018.10.058. Epub 2018 Nov 1.

Abstract

The blood-brain barrier (BBB) is a unique structure that controls substances exchange between the systemic circulation and the brain. Disruption of its integrity contributes to the development and progression of a variety of brain disorders including stroke, epilepsy and neurodegenerative diseases. It was shown that intracerebral thrombin level substantially increases following status epilepticus (SE). Inhibition of protease-activated receptor 1 (PAR1), the major thrombin receptor in the brain, produces an anti-epileptogenic and neuroprotective effects in an experimental model of temporal lobe epilepsy (TLE). Since serine proteases and PAR1 are implicated in the synaptic plasticity and memory formation, the aim of the present study was to elucidate the involvement of PAR1 in synaptic plasticity and behavior deficits following SE. Using lithium-pilocarpine model of TLE, we demonstrate that inhibition of PAR1 rescues SE-induced synaptic plasticity deficits in CA1 region of hippocampus. Although treatment with PAR1 antagonist does not ameliorate spatial learning deficits, it attenuates anxiolytic-like behavior in experimental rats after SE. Taken together; our data suggest an important role of PAR1 in SE-induced synaptic and behavioral alterations and provide a new insight into cellular mechanisms underlying behavioral impairments associated with epilepsy.

Keywords: Anxiety; Lithium-pilocarpine model; Protease-activated receptor 1; Spatial memory; Synaptic plasticity; Temporal lobe epilepsy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Behavior, Animal / drug effects
  • CA1 Region, Hippocampal / drug effects
  • CA1 Region, Hippocampal / physiopathology*
  • Disease Models, Animal
  • Epilepsy, Temporal Lobe / chemically induced
  • Epilepsy, Temporal Lobe / physiopathology*
  • Lithium / administration & dosage
  • Long-Term Potentiation*
  • Male
  • Pilocarpine / administration & dosage
  • Pyrroles / administration & dosage
  • Quinazolines / administration & dosage
  • Rats, Wistar
  • Receptor, PAR-1 / antagonists & inhibitors*
  • Status Epilepticus / chemically induced
  • Status Epilepticus / physiopathology*

Substances

  • N3-cyclopropyl-7-((4-(1-methylethyl)phenyl)methyl)-7H-pyrrolo(3, 2-f)quinazoline-1,3-diamine
  • Pyrroles
  • Quinazolines
  • Receptor, PAR-1
  • Pilocarpine
  • Lithium